GXDX Genoptix, Inc. (MM)

CARLSBAD, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Genoptix, Inc. (NASDAQ:GXDX), a specialized laboratory services provider, today announced it has been named the fastest growing company in Deloitte's prestigious Technology Fast 50 Program for San Diego, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2003-2007. Dr. Tina Nova, President and CEO of Genoptix, credits the Company's high-quality diagnostic services and expanding sales force with its 28,288 percent revenue growth from 2003-2007. The average increase in revenues during this period among companies that made the Technology Fast 50 for the region was 1,186 percent. "This recognition is a tribute to the outstanding performance of our employees and consultants, who have brought our world-class diagnostic services to oncologists and hematologists across the country," Dr. Nova said. "Their dedication has enabled us to achieve 16 consecutive quarters of solid growth in both case volumes and revenues through the first half of this year, and we continue to see potential for further growth in the years ahead." Founded in 1999, Genoptix has been profitable since the first quarter of 2007 and completed its initial public offering in November 2007. Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix's highly trained group of hematopathologists utilizes sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Genoptix reported revenues of $59.3 million, $24.0 million, $5.2 million, $0.7 million and $0.2 million in 2007, 2006, 2005, 2004 and 2003, respectively. To accommodate its growth, the Company is currently expanding its laboratory space by approximately 75 percent and plans to move its corporate office to a headquarters building adjacent to its laboratory facility in Carlsbad, Calif., by the end of December 2008. Genoptix expects to occupy approximately 100,000 square feet of laboratory and office space by year end. Companies in the regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, please visit http://www.fast500.com/. About Genoptix, Inc. Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California. For more information, please visit http://www.genoptix.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the potential for future growth, the success of the Company's business model, increasing case volumes and revenues, and the Company's ability to expand its laboratory facilities and consistently provide specialized, personalized and comprehensive diagnostic services. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, reimbursement decisions, compliance and regulatory risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within the Company's industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the full-year period ended December 31, 2007, most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company disclaims any intent or obligation to update these forward-looking statements. DATASOURCE: Genoptix, Inc. CONTACT: Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc., +1-760-930-7150, ; or Joleen Schultz, Principal of Mentus, +1-858-455-5500, ext 215, , for Genoptix, Inc. Web Site: http://www.fast500.com/ http://www.genoptix.com/

Copyright